Pune, Maharastra -- (SBWIRE) -- 08/25/2015 -- The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company profiles mentioned in this report are Allergan Plc, Foamix Pharmaceuticals Ltd., InSite Vision Incorporated, Kala Pharmaceuticals, Inc. and NicOx S.A.

Complete report available at http://www.rnrmarketresearch.com/blepharitis-pipeline-review-h2-2015-market

Scope of this report:

-The report provides a snapshot of the global therapeutic landscape of Blepharitis

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Blepharitis and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Blepharitis pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Order a copy of this report: http://www.rnrmarketresearch.com/contacts/purchase?rname=407982

(This is a premium report priced at US$2000 for a single user License.)

This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects.

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies. Identify and understand important and diverse types of therapeutics under development for Blepharitis. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content:

-List of Tables
-List of Figures
-Introduction
-Blepharitis OverviewTherapeutics Development
-Pipeline Products for Blepharitis - Overview
-Pipeline Products for Blepharitis - Comparative Analysis
-Blepharitis - Therapeutics under Development by Companies
-Blepharitis - Pipeline Products Glance
-Featured News & Press Releases